Evidence map›Paper›PMID 35805182›Full record

ArticleCells2022

Prevention of Cell Death by Activation of Hydroxycarboxylic Acid Receptor 1 (GPR81) in Retinal Explants.

Rupali Vohra, Berta Sanz-Morello, Anna Luna Mølgaard Tams, Zaynab Ahmad Mouhammad, Kristine Karla Freude, Jens Hannibal, Blanca Irene Aldana, Linda Hildegaard Bergersen, Miriam Kolko

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Rupali VohraDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Berta Sanz-MorelloDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Anna Luna Mølgaard TamsDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Zaynab Ahmad MouhammadDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.ORCID 0000-0003-3150-9961
Kristine Karla FreudeDepartment of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg, Denmark.ORCID 0000-0001-9480-2386
Jens HannibalDepartment of Clinical Biochemistry, Bispebjerg Hospital, University of Copenhagen, 2400 Copenhagen, Denmark.
Blanca Irene AldanaDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Linda Hildegaard BergersenBrain Energy Muscle Group, University of Oslo, NO-0318 Oslo, Norway.
Miriam KolkoDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.ORCID 0000-0001-8697-0734
University of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgressive retinal ganglion cell (RGC) dysfunction and death are common characteristics of retinal neurodegenerative diseases. Recently, hydroxycarboxylic acid receptor 1 (HCA

methodsRetinal explants were treated with 5 mM of the HCA

resultsHCA

conclusionThe present study reveals that activation of HCA

Indexed as

Nitric OxideRetinal DegenerationAdenosine TriphosphateAnimalsCell DeathGlutamic AcidLactic AcidMiceReceptors, G-Protein-CoupledAdenosine TriphosphateGlutamic AcidLactic AcidNitric OxideReceptors, G-Protein-CoupledATPcell deathenergy metabolismglucoseglutamate excitotoxicityGPR81HCA1lactateretinaretinal ganglion cells

Identifiers

PMID35805182
PMCPMC9265426
OpenAlexW4283781654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.